Sagar Bhagwat, MBA, MS

CRS:

BJMC

Role:

Administrative and Finance

Position:

Senior Grants and Contracts Analyst

Mr. Bhagwat is the Senior Grants and Contracts Analyst for Johns Hopkins Center for Clinical Global Health Education (CCGHE) and manages the financial activities of the center along with the Fiscal Operations Manager. He works on all aspects of sponsored research pre and post award, including development and management of federal, state, private, and foundation grants/contracts. He is the primary contact for all outgoing CCGHE subcontracts and works closely with international collaborators in India, Uganda, United Kingdom as well as domestic collaborators within the US.
 
Mr. Bhagwat is a part of the CCGHE leadership group that provides financial/administrative support and oversight to the Johns Hopkins entities in India (Johns Hopkins India Pvt. Ltd & Johns Hopkins India Foundation). He works closely with external funding agencies such as US National Institutes of Health (NIH), CRDF Global, Maryland Department of Health (MDH) among others and internally with the Office of Research Administration (ORA), the Office of Sponsored Projects and Shared Services (SPSS), the Department Finance Office at the Johns Hopkins University School of Medicine.
 
He joined Johns Hopkins in 2016 with several years of accounting and finance experience. He received a dual Master’s degree in Business Administration (MBA in Operations Management) and Science (MS in Chemical & Biomedical Engineering) from the Cleveland State University.

Categories

Leadership Committees
CRS
Roles

Clinical Trials

NWCS 408: Examining Longitudinal Cytokine Profiles in HIV-TB...

Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...

Read More

P1108: A Phase I/II, Open-Label, Single Arm Study to...

This purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of bedaquiline (BDQ) in...

Read More

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More

P2010: Phase III Study of the Virologic Efficacy and Safety...

IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...

Read More

A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Read More